← ANALYST RATINGS · TIPRANKS
Nuvation Bio (NUVB): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $14.57, the highest $21.00, the lowest $11.00. The average is +227.4% from the last price of $4.45.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 → $4.50−18.2% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.00 → $4.50−10.0% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.50 → $4.50−18.2% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $5.00 → $4.50−10.0% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 → $4.50−18.2% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $4.50−10.0% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $12.00 | Buy | +169.7% | Reiterated | 15.10.26on TipRanks Oct 16 05:40 | +1.2%next day −5.2% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $20.00 | Buy | +349.4% | Reiterated | 12.10.26on TipRanks Oct 13 21:45 | −1.9%next day −3.7% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $20.00 | Buy | +349.4% | Reiterated | 08.10.26on TipRanks 21:45 | +0.4%next day −1.9% · 5 days −9.0% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $5.50−26.7% | Hold | +23.6% | Reiterated | 03.10.26on TipRanks 13:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.00 → $5.50−21.4% | Hold | +23.6% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $5.00−33.3% | Hold | +12.4% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.00 → $5.50−21.4% | Hold | +23.6% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 → $5.00−28.6% | Hold | +12.4% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $5.00−33.3% | Hold | +12.4% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.00 → $5.00−28.6% | Hold | +12.4% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $12.00 | Buy | +169.7% | Initiated | 30.09.26on TipRanks 06:15 | −0.2%next day −0.9% · 5 days −15.1% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | — | Buy | — | Reiterated | 15.09.26on TipRanks 13:36 | −1.9%next day +0.1% · 5 days +2.8% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $11.00 | Buy | +147.2% | Reiterated | 15.09.26on TipRanks 09:16 | −1.9%next day +0.1% · 5 days +2.8% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 15.09.26on TipRanks 07:45 | −1.9%next day +0.1% · 5 days +2.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $7.00−6.7% | Hold | +57.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 | Hold | +68.5% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $7.00−6.7% | Hold | +57.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 | Hold | +57.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 | Hold | +68.5% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $7.00−6.7% | Hold | +57.3% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | $12.00 | Buy | +169.7% | Initiated | 21.08.26on TipRanks 06:17 | +1.1%next day −2.2% · 5 days −4.4% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $12.00 → $14.00+16.7% | Buy | +214.6% | Reiterated | 07.08.26on TipRanks 09:01 | +7.4%next day 0.0% · 5 days −6.2% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $21.00 | Buy | +371.9% | Reiterated | 07.08.26on TipRanks 07:06 | +7.4%next day 0.0% · 5 days −6.2% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $19.00 → $20.00+5.3% | Buy | +349.4% | Assigned | 06.08.26on TipRanks Aug 7 07:06 | −3.9%next day +7.4% · 5 days −1.4% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $12.00 | Buy | +169.7% | Reiterated | 06.08.26on TipRanks 18:46 | +7.4%next day 0.0% · 5 days −6.2% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | — | Buy | — | Reiterated | 01.06.26on TipRanks 13:00 | +3.5%next day −1.3% · 5 days −0.7% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $10.00 → $7.00−30.0% | Hold | +57.3% | Reiterated | 03.03.26on TipRanks 08:45 | −24.5%next day +8.0% · 5 days +8.0% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $12.00 | Buy | +169.7% | Reiterated | 26.11.25on TipRanks 14:05 | +1.0%next day −0.3% · 5 days +3.1% | ↗ |
| Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% | Citizens JMP | $8.00 → $10.00+25.0% | Buy | +124.7% | Reiterated | 20.11.25on TipRanks 06:30 | −0.4%next day −1.3% · 5 days +9.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Nuvation Bio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.57 at a price of $5.60 (+160.2%); now: $14.57 at $4.45 (+227.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 22 | 15 | 14 | 14 | 14 | 12 |
| Buy | 2 | 4 | 4 | 3 | 3 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.12 (from $-0.15 to $-0.09). Last quarter: $-0.18.
Sales
Next quarter’s sales estimate — $35M (from $28M to $40M). Last quarter: $32M.
Best top-analyst consensus in the sector · Healthcare
About Nuvation Bio
- CEO: David T. Hung
- Employees: 305
- 1500 Broadway, New York City, NY, 10036, US
- www.nuvationbio.com
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Data from the stock’s TipRanks forecast page, read 0 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗